Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD)
Diseases and Conditions Researched
Hepatic Veno-Occlusive Disease; Hodgkin's Lymphoma; Leukemia, not otherwise specified; Multiple Myeloma; Non-Hodgkin's Lymphoma
What is the purpose of this trial?This is a multicenter, single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. The primary objective of this Treatment IND is to provide Defibrotide under 21 CFR 312.34 ("Treatment use of an investigational new drug"). The Treatment IND will collect additional usage, tolerability and safety data from patients with VOD. Efficacy analysis will be done for patients who meet eligibility criteria for the previous Phase 3 study "Protocol 2005-01 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients: A Historically Controlled, Multi-Center Phase 3 Study to Determine Safety and Efficacy". Additional safety data collected from all patients who receive a dose of Defibrotide will be used to support the New Drug Application and the labeling for Defibrotide.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.